- Advertise
- OLE Scientific Interchange Workshops
- About OncLive
- Editorial Board
- CureToday.com
- TargetedOnc.com
- CancerNetwork.com
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2021 MJH Life Sciences™ and OncLive. All rights reserved.
UT Health San Antonio MD Anderson Cancer Center | Strategic Alliance Partners
Latest from UT Health San Antonio MD Anderson Cancer Center
Mesa and Gerds Talk Management Strategies and Emerging Agents in Myelofibrosis
February 04, 2021
Podcast
Dr. Mesa and Dr. Gerds provide insight into the current utility of JAK inhibitors in myelofibrosis, unmet needs, and novel agents and combination strategies in the pipeline.
Momelotinib Trial Seeks to Address Myelofibrosis Symptoms
January 06, 2021
Article
January 6, 2021 - The MOMENTUM trial will randomize patients to receive momelotinib or danazol to determine which regimen shows more efficacy against the MF hallmarks of anemia, constitutional symptoms, and splenomegaly.
Dr. Mesa on the Anticipated Utility of Momelotinib in Myelofibrosis
December 07, 2020
Video
Ruben A. Mesa, MD, discusses the anticipated utility of momelotinib in myelofibrosis.
Dr. Mesa on the Potential Role of Momelotinib for Myelofibrosis-Associated Anemia
December 01, 2020
Video
Ruben A. Mesa, MD, discusses the potential role of momelotinib in alleviating myelofibrosis-associated anemia.
Dr. Mesa on Management Strategies for MPNs
October 23, 2020
Video
Ruben A. Mesa, MD, discusses management strategies for patients with myeloproliferative neoplasms.
Dr. Mesa on the Rationale for the Earlier Use of Ruxolitinib in Myelofibrosis
October 16, 2020
Video
Ruben A. Mesa, MD, discusses the rationale for the earlier use of ruxolitinib in myelofibrosis.